Bioventix Share Discussion Threads

[boros10] 21/1/2015 16:19

New sensitive Troponin tests all over the news today. Augurs well for the high affinity troponin test being developed by Bioventix's global top five diagnostic partner set for launch in 2016/17 in Europe and the US in 2017. http://medicalresearch.com/heart-disease/highly-sensitive-troponins-improve-er-diagnosis-of-heart-disease/10591/http://www.telegraph.co.uk/news/nhs/11358339/New-test-could-detect-twice-as-many-heart-attacks-in-women.htmlhttp://www.dailymail.co.uk/health/article-2919080/20-heart-attack-test-save-thousands-women.http://www.bbc.co.uk/news/health-30896795

[igbertsponk] 21/1/2015 10:41

Good timing !

[bamboo2] 21/1/2015 10:41

That's covered the spread nicely. :)

[bamboo2] 21/1/2015 10:10

Back in here. Shame to have missed some of this share price rise, but very fortunate to have put the proceedings from my earlier sale into xsg, which has done okay.

[igbertsponk] 19/1/2015 15:52

Looks like the gradually inching up has now turned into a bit of a surge.

[bamboo2] 11/1/2015 11:37

Is there a six month update or any other news due?

There was one 31 December in previous years. I think the rules may have changed regarding updates.

[Looking to try and time my buying back in here already!]

[dasv] 09/1/2015 16:00

no worries bamboo2. I'm not selling.

[bamboo2] 09/1/2015 15:01

Sold mine today, because wanted the capital for a different share, but will be back again. Thanks dasv for the reco.

[jakedog2] 09/1/2015 14:50

Well, taken an initial position. Saw Leon Boros tweet about the company in Oct, but was too slow to investigate, so missed the rise.

Then it showed up again on my ROC, ROE, Op Margin screener. No sign of moving down, so taken the plunge

Ticks lots of boxes but risks is the fact there is the actual size of the team (x11) & lack of liquidity

[impvesta] 01/12/2014 12:43

Not much share price action here since I bought in nearly a couple of weeks ago, following the Mello Derby event....in fact no movement whatsoever! However I notice that a deal has gone through this morning above the offer price, 736.293 compared to the lowest quoted offer price of 735.

AGM on Wednesday, but I won't be there I'm afraid. Are any of the small band of followers on this BB planning to attend? Not sure if there will be a trading update of any sort. It doesn't look as if there was any trading update at last year's AGM.

[markgahagan] 12/11/2014 17:06

I have made an investment in this one. As well as all of the excellent commentary above I just love that this company makes so much money on it's retained earnings as well as on existing assets. Could not resist that.

[pj 1] 06/11/2014 21:20

Well, its now on the watchlist following Mello today

But what an enigma of a company at first glance and introduction.

Take this with a large pinch of salt but it looks to me like to Company (all 11 of them?) could do absolutely nothing for 5 years and still generate growing cash reserves (subject to dividends).

The CEO seems to like sheep too which is a shame (Forest fan) :-// I shall not elaborate further at this point)

[dasv] 06/11/2014 10:21

hatter2 - yes I was alerted to the stock from that interview. I would like to see Leon Boros at the Mello2014 event - he is talking before BVXP on QARP (quality at a reasonable price). Unfortunately won't be able to come.

[hatter2] 06/11/2014 09:48

dasv, yes the liquidity on small companies is often an issue especially when adverse news is announced.

The free float is listed as 74% which I am ok with as it implies that those running the company are well tuned in to it’s success. I agree that some of the numbers in terms of operating margin and free cash flow are quite outstanding.

I can’t get along to the Mello2014 event myself but would be interested to hear how their presentation was accepted by those in attendance.

Incidentally a very positive mention from Leon Boros; I suppose you have already seen it but in case not, link attached:

[dasv] 06/11/2014 07:24

hatter2 - I am very excited by the fundamentals of this company, e.g. cash flow, earnings track record. I've rarely seen such great margins in a UK stock. It's my current pick in the SHA thread 2014 comp. It would be nice if the liquidity was better but I guess that's par for the course for shares in companies of this sort of market cap.

[hatter2] 06/11/2014 02:06

dasv, interesting and exciting stock yet such a small following of interested investors/potential investors: possibly not exciting enough for some!

I see from davidosh they are presenting at Mello2014

[dasv] 05/11/2014 22:25

I doubled up last week

[hatter2] 05/11/2014 15:26

Some of the numbers look a little steep to me in terms of my normal screening for shares but there are several points that have made this stock an exception for me and convinced me to buy in. The points that impress me and made the case for purchase a compelling one are:
firstly the science and the edge that BVXP have built up: a moat!
the splendid margin of 60%
ROCE of in excess of 40%
Incredible cash flow figures
Cash on the books and zero debt
a projected yield of almost 4%

Just so much that I like about this stock.
These notes are just my views and certainly not investment advice: please DYOR as usual.

[igbertsponk] 05/11/2014 11:02

Keeps ticking up this, must be good demand from someone accumulating.

[99matti99] 04/11/2014 11:47

Thanks Igbert. Geees Barclays can be inexcusably slow with divis.

[igbertsponk] 04/11/2014 11:36

Yes, last Friday.

[99matti99] 04/11/2014 11:30

Have people received the divi?

[housemartin2] 21/10/2014 18:06

Boros10. Thanks for taking the trouble to respond. As Royalties are forming a growing part of Sales, then this accounts for not just the absolute increase in debtors but the proportional increase as well.
The high and growing debt to sales ratio is particularly high at the half year which may reflect different customers than at the year end who supply data later I guess ?
I doubt that I can make it to the Derby Mello (and I have not bought a ticket even though it is only 50 miles away for me ) but I look forward to any interesting feedback.
HM2

[boros10] 19/10/2014 21:24

Housemartin2. Bioventix only get to invoice royalties twice a year based on the sales of its customers diagnostic test kits which include the Company's sheep monoclonal antibodies. It takes time for the sales data to reported, sometimes a couple of months after the period end. Invoices are then issued and are paid quickly. As royalties have grown so have debtors but if the Company's year end was three months earlier or later its debtors would be minuscule. 99matti99 - Troponin. No figures have been provided by the Company or its brokers but Peter Harrison made clear at the meeting how important it is to the Company's future growth.

[housemartin2] 19/10/2014 18:31

I see that debts are rising significantly faster than Sales both this year and last. Has anyone got any insight into this ? - it just leaped out at me in an otherwise great set of accounts.

I am new to this company so apologies if this is a Known known.